1. Medtech Insight

J&J Remains Optimistic Despite 5% Decline In First-Quarter Device Sales

 
• By Reed Miller

The company expects the COVID-19 pandemic will cost its device businesses between $4bn and $7bn in revenue in 2020, as most non-urgent procedures are postponed.

SC2004_JNJ Sign_1524542537_1200.jpg
• Source: shutterstock.com

Johnson & Johnson expects its medical device businesses to begin recovering from the damage caused by the COVID-19 pandemic by the end of 2020.

Demand for many types of medical devices declined sharply in the first quarter as hospitals and clinics around the world...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Medtech Insight

Finland Cracks Down On Software That Needs Regulating As A Medical Devices

 
• By Amanda Maxwell

Finland has initiated a project to improve the effectiveness of the monitoring of software intended for medical use and to ensure that software placed on its market meets the requirements set for it. 

Milner Pitch Day: Multiomic Pathology, Microcancer Avatars And Cell Morphology Intelligence

 
• By Natasha Barrow

The Milner Institute, the on-campus hub for start-up acceleration at Cambridge University, hosted its annual Pitch Day on July 1. Start-ups Panakeia, PathwayBio and Sentinal4D presented diagnostic technologies.

Investors Urged To Prioritize Patient Engagement To Ensure Clients’ Products Succeed

 
• By Amanda Maxwell

To succeed in medtech, investors must focus on patient outcomes. Gilde Healthcare says involving patients boosts product effectiveness, access and market success — making it a smart strategy in today’s strained healthcare systems.